asa glp 1 agonists GLP-1 receptor like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) have become A narrative review of glucagon-like

The patients who will do best on these medications over the long term are those who use them within a framework that protects lean mass, supports metabolic health, and addresses the behavioural and physiological underpinnings of weight regain

(2025) Figure 2: Created in BioRender

An interesting cross-talk between the glucagon-like peptide-1 receptor axis and angiotensin receptor pathway for modulation of renal sodium handling in obesity

(2) intervention (exposure) and comparator: SGLT2 inhibitor or GLP-1 receptor agonist monotherapy versus placebo or metformin as a first-line drug

A novel cardiometabolic therapeutic prospect Cardiometabolic diseases as diabetes mellitus, heart disease, overweight, obesity, hypertension, hyperlipidemia and its multiple macro and microvascular complications (ischemic cardiomyopathy, stroke, chronic kidney disease, retinopathy, peripheral neuropathy, etc.) are conditions closely related to each other and constitute at present time the leading cause of morbility, disability and death in the world [28]